{
  "ticker": "VERA",
  "company_name": "Vera Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06983028",
      "title": "Atacicept in Multiple Glomerular Diseases",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "pMN, IgAN, Nephrotic Syndrome, MCD, FSGS",
      "start_date": "2025-07-07",
      "completion_date": "2027-11",
      "enrollment": 0,
      "sponsor": "Vera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06674577",
      "title": "A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "PHASE2",
      "condition": "IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease",
      "start_date": "2024-12-01",
      "completion_date": "2028-05-31",
      "enrollment": 0,
      "sponsor": "Vera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT04294472",
      "title": "A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "BK Virus Infection",
      "start_date": "2020-08-05",
      "completion_date": "2022-02-10",
      "enrollment": 0,
      "sponsor": "Vera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07020923",
      "title": "Monthly Dosing of Atacicept in IgAN",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "IgA Nephropathy (IgAN), Berger Disease",
      "start_date": "2025-05-29",
      "completion_date": "2027-09",
      "enrollment": 0,
      "sponsor": "Vera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT04716231",
      "title": "Atacicept in Subjects With IgA Nephropathy",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "IgA Nephropathy, Berger Disease",
      "start_date": "2023-06-29",
      "completion_date": "2028-07",
      "enrollment": 0,
      "sponsor": "Vera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05609812",
      "title": "Atacicept in Subjects With Active Lupus Nephritis (COMPASS)",
      "status": "WITHDRAWN",
      "phase": "PHASE3",
      "condition": "Lupus Nephritis (LN)",
      "start_date": "2022-11-02",
      "completion_date": "2028-12-15",
      "enrollment": 0,
      "sponsor": "Vera Therapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 6,
    "by_phase": {
      "PHASE2": 4,
      "PHASE3": 2
    },
    "by_status": {
      "RECRUITING": 2,
      "ENROLLING_BY_INVITATION": 1,
      "COMPLETED": 1,
      "ACTIVE_NOT_RECRUITING": 1,
      "WITHDRAWN": 1
    },
    "active_trials": 4,
    "completed_trials": 1,
    "conditions": [
      "BK Virus Infection",
      "IgA Nephropathy (IgAN), Berger Disease",
      "IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease",
      "IgA Nephropathy, Berger Disease",
      "Lupus Nephritis (LN)",
      "pMN, IgAN, Nephrotic Syndrome, MCD, FSGS"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:22:46.060752",
    "search_query": "Vera Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Vera+Therapeutics,+Inc."
  }
}